Qinhao Pharmaceuticals, an R&D-centric enterprise committed to pioneering the next generation of global anti-tumor small-molecule drugs, proudly announced today the successful closure of a Crossover round financing, raising in excess of RMB 300 million. This pivotal funding round was spearheaded by Songhe Capital, with significant contributions from a consortium of esteemed institutions.

As a biotech firm driven by self-innovation, Qinhao Pharmaceuticals is at the forefront of developing globally leading targeted anti-tumor small-molecule drugs. Embracing a drug development philosophy centered on "AI/Biology-Driven Smart Design," the company has established a highly efficient R&D system, constructed a diversified pipeline, and propelled multiple projects into clinical trials, garnering widespread acclaim from various stakeholders.

This infusion of capital will significantly expedite Qinhao Pharmaceuticals' R&D endeavors and strategic expansion. Looking ahead, Qinhao Pharmaceuticals will leverage its AI-powered platform, zero in on unmet clinical needs, and forge partnerships across sectors to fuel the advancement of innovative drugs, ultimately offering groundbreaking treatment solutions to patients in need.